You are here:
Company

ViroTact

Back to overview

ViroTact has developed an innovative molecular diagnostic test to show the presence of Covid-19. The technique enables quick, scalable and affordable point-of-care testing, which allows the number of tests in the Netherlands and worldwide to be scaled up. The technology is based on an existing patented platform technology for detecting proteases that are produced by viruses or bacteria. The test consists of an innovative substrate that emits near-infrared light in the presence of viral protease. This light is then captured and measured by a specially developed portable detector. Thanks to the detector, the test can be used as a practical point-of-care test that can be used by GPs, in emergency rooms or at the bedside of hospital patients. Other conceivable settings include airports and schools.

ViroTact belongs to the fund:

Carduso Capital B.V.">

Carduso Capital participates in technology companies that are preferably based on the know-how represented in and originating from the Groningen science cluster in and around the University of Groningen (RUG) and the ...

View all the funds from the IFG

...
NextGen Ventures 2 invests in knowledge-intensive data-driven companies that are changing healthcare – preferably ...